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Abstract 
Boron Neutron Capture Therapy (BNCT) is a promising targeted 
chemo-radiotherapeutic technique for the management of invasive brain 
tumours, such as glioblastoma multiforme. Prerequisite to effective BNCT is 
the selective targeting of tumour cells with 10B-rich therapeutic moieties. To 
this end, polyhedral boranes, especially carboranes, have received 
considerable attention since they combine high boron content, relative low 
toxicity and metabolic inertness. This article reviews progresses in the 
molecular design of recently investigated carborane derivatives in light of the 
widely accepted performance requirements for effective BNCT. 
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The principles of Boron Neutron Capture Therapy 
 
BNCT is a two-step targeted chemo-radiotherapeutic technique that 
involves the selective delivery of 10B-rich agents to cancer cells for the 
purpose of their selective destruction through subsequent irradiation with low-
energy neutrons, which initiate highly localised nuclear fission reactions that 
do not damage surrounding tissue (Figure 1).  
 
Figure 1.  
 
Integral to successful BNCT is the selective uptake of a therapeutic 
dose of the boron-containing agent by cancer cells.  At a neutron fluence of 
1012 neutrons/cm2, and ignoring the micro-distribution of the drug, this is 
calculated at 30 μg of 10B/g of tumour (about 109 atoms of 10B per cell).1 In 
order to minimise damage to the vascular endothelial cells and to white 
matter, the ratios of tumour/blood and tumour/surrounding tissue 
concentrations must both be higher than 3:1.2 Monte Carlo simulations  have 
shown that boron accumulated within the cell nucleus has little effect on 
neighbouring cells and it is more effective in inducing cell death (ca. 2.5×) 
than the same amount of boron distributed uniformly within the entire cell.3 
This suggests that the mechanism of neutron bombardment-initiated damage 
is determined by the intracellular location occupied by the boronated agent. 
Similarly, calculations have shown that boron localised at the cell surface has 
a ca. 10% lower killing effect than an equimolar quantity of boron that is 
uniformly distributed within the entire cell.3 Irradiation of the localised 
boronated agent with a beam of thermal neutrons leads to each 10B atom 
capturing a neutron to form 11B*, which in turn undergoes nuclear fission to 
release the energy that induces localised tumour cell necrosis. Consequently, 
the nuclear reaction of 10B can effect the selective destruction of malignant 
tumour cells without compromising the surrounding healthy tissue. The 
probability of a nuclide capturing a neutron is enumerated by the “neutron-
capture cross section” (σth, measured in barns; 1b = 10-24 cm2). Offering a 
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good compromise between toxicity and stability, 10B is characterised by σth = 
3838 b.4 As compared with X-ray methods, the use of neutron beams is 
preferred for treatments involving hypoxic cells5 since  the oxygen 
enhancement ratio (the ratio of radiation doses required to effect the same 
rate of cell death under oxic as under hypoxic conditions) of neutrons is 1.6 
which is lower than that of X-rays (2.5 to 3.0).  
The interaction between neutrons and 10B nuclei generates recoiling 7Li 
nuclei and α-particles (also termed Linear Energy Transfer (LET) radiation), 
which are highly efficient in effecting cell death.6  Since α-particles are equally 
lethal to hypoxic or oxygenated malignant cells as they are to surrounding 
tissue, in order to maximise the relative biological effectiveness the cytocidal 
effects of the BNCT capture reaction must occur primarily in malignant cells 
that have preferentially accumulated therapeutically useful amounts of 10B. 
Consequent to the short path lengths (4.5 to 10 m) of LET, the lethal effect is 
confined to the host cell7.  Inevitable proton capture reactions that involve 1H 
and 14N atoms produce γ-rays and protons, respectively, but the σth values of 
these nuclei are too small to be of significance in the therapy of cancer.8 
Because of their greater capability to penetrate tissue, epithermal neutrons 
have been replacing thermal neutrons – thermal neutrons are unable to act on 
tumours located below the tissue surface because of scattering effects. 
Epithermal neutrons, which are more energetic (0.5 eV-1.0 keV range) than 
thermal neutrons, do not suffer from the disadvantages of H-recoil processes 
and consequently allow capture reactions to occur at some distance within the 
tissue: epithermal neutrons are progressively slowed into thermal neutrons 
through heat-releasing interactions with the hydrogen atom constituents of 
biological tissue that do not caused damage to biological tissue.9 
 
 
 
Applications and limitations of BNCT 
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Although there has been interest in the application of BNCT for the 
treatment of skin11 and liver12 tumours, most studies to date have been 
focused on the treatment of brain tumours, especially glioblastoma multiforme 
(GBM);13 characterised by rapid regeneration of tumour cells and highly 
efficient DNA repair mechanisms, the condition is intrinsically resistant to 
treatment.14,15 Since BNCT is associated with the induction of sublethal 
damage and potentially lethal damage to a non-repairable extent, it has been 
argued that the technique may act in synergy with surgery.16 
The multitude of performance requirements that 10B-containing agents 
need to satisfy is reflected in the very small number of compounds that have 
been tested in the clinic. The limited clinical success of BNCT has been 
attributed to the: absence of sound procedures for the prediction and 
estimation of radiobiological effectiveness; inefficient methods for the 
optimization of drug delivery17 and dosimetry;18 random distribution and 
subcellular localisation of the 10B-containing agents; and, limited availability of 
suitable neutron sources.19,20 Key examples of clinical trials for the treatment 
of GBM by BNCT has been presented by Hosmane et al.20 
 
BNCT agents 
 
It has been argued2 that an ideal BNCT agent should: be systemically 
non-toxic; be selective in targeting tumour cells (ideally accumulating within 
specified subcellular structures); persist intracellularly for a period of time that 
is consistent with the practicalities of the irradiation protocol; deliver the 
therapeutically optimal amount of ~109 10B atoms/cell; persist at 
tumour/normal tissues and tumour/blood ratios that are higher than 3:1 and 
5:1, respectively; and, be capable of crossing biological membranes (most 
importantly, the blood brain barrier). To this end, polyhedral boranes have 
received considerable attention as the molecular moieties of choice for the 
development of therapeutic agents.21 Among these, carboranes22 (icosahedral 
dicarba-closo-dodecaboranes, C2B10H12; the focus of this review) are of 
particular interest since their high 10B content is combined with good catabolic 
stability and low toxicity. Also, these materials are amenable to fine tuning 
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through chemical functionalization at each vertex by means of well 
established chemical methodologies, which have been reviewed 
elsewhere.23,24  
 
Historical perspective: a promising start 
 
Attempts have been made to classify boronated agents according to 
key biological properties25 but the most widely used system for their 
classification is chronological. Boron compounds are grouped into three 
generations: the first generation includes water-soluble salts of inorganic 
borates; the second generation reflects the introduction of polyhedral boranes; 
and the third generation encompasses agents that exploit the biochemical 
pathways through which boronated biomolecular analogues may be 
accumulated in subcellular structures.  
The first generation of BNCT agents included sodium borates,26 such 
as borax and pentaborate, and boric acid. These agents presented a lack of 
selectivity, little persistence in tumour cells and low boron to tumour 
concentration ratio, which led to their failure, in the 1950s, to progress through 
clinical trials.25 Consequent to the observation that para-carboxyphenylboronic 
acid (PCPB)27 is not metabolized by the body, and is excreted unchanged 
through urine, this material was proposed as a candidate agent for BNCT. In a 
parallel development, para-borophenylalanine (BPA; compound 1, Figure 2), a 
material synthesised by Snyder et al., presented another BNCT candidate 
material due to its structural similarity to phenylalanine (compound 2, Figure 
2).28  
  
Figure 2.  
 
The use of BPA is associated with favourable tumour/blood ratios, but it 
was not until the early 1980s that Mishima29, taking advantage of BPA’s 
structural similarity to melanin precursors, started a programme of research 
on the applications of BPA in the treatment of melanomas. By the early 1990s 
Coderre et al.30 had begun to use BPA for the treatment of brain tumours.  
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A major development in the chemistry of boron is represented by the 
discovery, by Hawthorne et al.,31 of the polyhedral borane anions  
decahydrodecaborate ([B10H10]2-) and dodecahydrododecaborate ([B12H12]2-). 
Consequent to their aromatic-like nature, these non-planar compounds 
display remarkable chemical stability. Sodium decahydrodecaborate 
(Na2B10H10; GB-10) was recognised immediately as a potential clinical agent 
for BNCT, since it is less toxic than boric acid (respectively, for GB-10 and 
boric acid, LD50 = 1.04 and 2.11 g/kg of body weight) and it presents more 
favourable tumour/normal cells concentration ratios.33 This molecule, 
however, did not meet its promise in clinical tests involving humans, which in 
turn had significant implications for the direction of BNCT research. The 
negative results from these trials revealed the sensitivity of the vascular 
endothelium to LET particles and highlighted the significance of boron 
concentration in blood during irradiation.34 
Screening experiments35 designed to select drugs that give favourable 
tumour/blood concentration ratios identified the selective tumour-cell uptake of 
sodium dimercaptooctachlorodecaborate (1,10-Na2B10Cl8(SH)2; compound 3, 
Figure 2) and sodium mercaptoundecahydrododecaborate (BSH; compound 
4, Figure 2). The impetus for further studies was provided by speculation, at 
the time, that the capability to recognize tumour cells and to promote 
accumulation may be inherent to the boron cluster structure, or may be linked 
to ionic charge, or to a specific interaction with certain proteins. The 
associated research efforts resulted in a third generation of boron compounds, 
which have been the primary focus of research over the last two decades. 
Boron compounds of this generation are designed such that they are 
rendered capable of reaching and binding to tumour cell receptors efficiently 
and selectively. Molecular design strategies have evolved to include the 
selective targeting of epidermal growth factor receptor, mitochondria, 
lysosomes, and tumour cell nuclei.36,37 Integral to molecular design 
considerations has been the effect of the BBB on the transport of the active 
ingredient to the brain. The assumption that the BBB becomes permeable to 
therapeutic agents due to the leaky vasculature of brain tumours was quashed 
by the observation that isolated clusters of tumour cells, protected by the 
normal BBB, allow tumour reoccurrence.38 
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From this generation of molecules, two have been advanced to the 
clinical stages of research, namely: BPA and BSH39. BPA has been evaluated 
as an agent for the treatment of melanomas40, gliomas, sarcomas41, and 
meningiomas42; most commonly as a complex of fructose (BPA-F). Evidence 
has been presented that BPA-F is taken up through the metabolic pathways of 
the tumour, and also that it displays highly selective accumulation in tumours, 
low toxicity, few side effects, and, most importantly, that it is capable of 
crossing the BBB43. BPA-F has been shown to achieve tumour/blood and 
tumour/brain concentrations ratios of ca. 3.5/1 in 9L gliosarcoma (rat model);44 
cell ablation has been investigated.45 Several studies have been carried out 
on the intracellular distribution of BPA and according to Nguyen et al.46 BPA 
accumulates prevalently in the cytosol but also in the nucleus. In an effort to 
improve the absolute and relative uptakes of boron in gliomas, the effects of 
dose and infusion time of BPA on the selectivity of delivery have been 
investigated.47 The use of BPA allowed researchers to access tumour boron 
levels of 70 μg 10B/g of tumour mass; improvement in therapeutic gain were 
achieved either by increasing the concentration of boron within the tumour or 
by increasing the tumour/blood concentration ratio.48 The route and the 
administered dose are known to influence therapeutic gain,49 as demonstrated 
by studies on the pharmacokinetics and pharmacodynamics of BPA.50 The 
chemistry of BPA has been reviewed by Sivaev and Bregadze.51 
BSH is a small hydrophilic anion, which in contrast to BPA, does not 
cross the BBB,52 Used in infusion for the treatment of GBM, BSH has been 
shown to be not toxic and to be taken up by the tumour in reasonable 
amounts (tumour/brain ratio >3/1; tumour/blood ratio 0.9/1 - 2.5/1).53 Slow 
continuous intravenous infusion was identified as a safer and more efficient 
means of achieving a high concentration of boron. This technique leads to 
BSH uptake in malignant gliomas that is about three times higher than that in 
low grade gliomas.53 The clinical application of BSH is generally associated 
with Hatanaka54 and Nakagawa,55 who concentrated their efforts in the 
intracarotidal injection of BSH (typically 30-80 mg/kg of body weight). Tumour 
sampling after neutron irradiation indicated a high presence of BSH (up to 60 
μg of 10B/g of tumour). Hatanaka’s clinical research resulted in the successful 
treatment of grade III and IV gliomas, with several long-term survivors, 
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including a male patient who survived for more than 24 years.55 Hatanaka’s 
pioneering work led to many clinical BNCT investigations of BSH as a 
treatment for GBM.56,57,58 The work has been extended to a study that 
involved the co-administration of BSH with BPA.59 
 
 
 
Carboranes 
 
Carboranes are isoelectronic and isostructural with the 
dodecahydrododecarboronate (B12H12)2- anion and present aromatic 
behaviour.22,60 The neutral lipophilic icosahedral dicarba-closo-
dodecarboranes (C2B10H12), whose first synthesis was reported independently 
by workers in the USA61 and in the former USSR,62 exist in three isomeric 
forms: ortho (compound 5), meta (compound 6) and para (compound 7); 
Figure 2.  
The carborane structure consists of two carbon and ten boron atoms 
that are arranged in an icosahedral geometry in which both carbon and boron 
are hexacoordinate.63 Owing to its lipophilic nature, the ortho isomer is the 
regarded as the moiety of choice for the molecular design of structures that 
may be capable of crossing the BBB.64 Carboranes are readily amenable to 
functionalisation. The boron vertexes are able to participate in electrophilic 
substitution reactions,65,66 such as halogenation. Additionally, protons on 
carbon atoms may be abstracted by a strong base (pKa (ortho) = 23.3, pKa 
(meta) = 27.9, pKa (para) = 30.0 - Streitwieser’s scale)67 to form carbon 
nucleophiles that can be utilised to create C-C linkages.68,69 Treatment with a 
strong base allows the ready conversion of any of the isomeric forms of closo-
carboranes into the corresponding hydrophilic nido-carboranes 8, 9, and 10 
(Figure 2) by means of a deboronation reaction.70 While the isomerization 
reaction of carboranes is not reversible, the transformation of nido-carborane 
to the corresponding closo-carborane is possible via a capping reaction.71 
Closo-carboranes have been investigated widely because of their high boron 
content and favourable pharmacokinetic properties, which altogether have 
rendered them promising candidate agents for use in medicinal chemistry.  
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Carborane chemistry: the search continues 
 
The significant interest in the synthesis of boronated analogues of 
biomolecules is consequent to the quest for therapeutic compounds with a 
capability to accumulate in subcellular structures. To this end, efforts towards 
the design of carboranyl compounds have concentrated on the mimicing of 
cellular building blocks (amino acids, sugars, etc.), such as to grant to boron 
access to cells via normal transport pathways as is exemplified by the classes 
of carboranyl compounds reviewed below. 
 
Amino acids 
Boron-containing amino acids have been investigated for their potential 
as BNCT pharmacophores. The observation by Endou and Kinai72 that L-
amino acid transport to the tumour tissue site is essential for tumour cell 
growth rationalised the synthesis of boron-containing alpha-amino acids, such 
as BPA and o-carboranyl-glycine.73 The range of synthetic congeners has 
been extended by Brattsev74 to ortho-carboranylalanine (CBA; compound 11; 
Figure 3). To the same end, Soloway75 proposed a more convenient route 
involving the phase-transfer alkylation of commercial N-(diphenylmethylene) 
aminoacetonitrile with propargyl bromide, followed by the boronation of the 
resulting product with decacarborane-acenitrile complex and subsequent 
hydrolysis. The same synthetic route has been employed for the preparation 
of para-(ortho-carboran-1-yl)-phenylalanine (CBPA; compound 12) and O-
(ortho-carboran-1-ylmethyl)-tyrosine (CBT; compound 13; Figure 3). 
Encouraging in vitro results prompted the in vivo testing of these molecules, 
which at respective tumour/blood concentration ratios of ca. 1.0 and 1.4 did 
not meet the performance requirements for further evaluation76 As a 
consequence of the discovery that the L-isomer of BPA accumulates 
selectively in melanoma cells, enantiomerically pure L-CBA was prepared,77 
but this material has not been assessed in the clinic because the inherent 
boron tumour/healthy cells concentration ratio is not within the therapeutically 
useful range. 
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Figure 3.  
 
Morris et al.78 evaluated the effect of L-BPA prescription dose on the 
central nervous system (CNS) of the rat model and concluded that a dose of 
1600 mg L-BPA/kg is required to optimise the healthy tissue to blood ratio of 
boron concentration.79 Efforts towards the optimisation of solubility in serum 
are informed by earlier attempts towards the improvement of the aqueous 
solubility of carboranyl aminoacids.73,80 Since human thymidine kinase 
1(hTK1) is expressed in proliferating cells, Hasabelnaby et al. 81 proposed the 
use of carrier-linked prodrugs of 3-carboranyl thymidine.82 Another approach 
towards the incorporation of boron into tumour-seeking molecules has been 
explored by the ring opening of cyclic oxonium derivatives of boron hydrides 
by means of the action of a nucleophilic agent. 83,84 
In common with naturally occurring amino acids, synthetic structures 
that combine R-amino acids and amino-boronic acids have been suggested 
as potential building blocks for BNCT,85,86 but the therapeutic promise of such 
compounds is yet to be demonstrated. Although the amount of research effort 
invested towards the development of new boronated amino acids has slowed 
considerably over the last decade, the approach remains validated by the 
promise of transport across biological barriers, such as the BBB, by dedicated 
carrier-mediated influx.  
 
  
Amines and amides 
The observation that organoboron compounds inhibit the 20S 
proteasome,87 and also some enzymes such as lipases,88 has provided the 
impetus for the chemical synthesis and biological evaluation of many 
boronated amines. Synthetic methodologies towards these materials 
commonly involve a metal-halogen exchange reaction between an 
organometallic intermediate and an aryl halide-functionalised chiral amine.87 
To ameliorate cytotoxicity and to effect increased boron concentration at 
tumour cells, Lee et al. 89 have suggested an approach that involves the fine-
tuning of the polarity of molecules through the manipulation of their capability 
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to participate in N-H-O bonding. The approach led to compounds that exhibit 
low cytotoxicity (IC50 in the range 0.2-0.7 mM) and which effect in cancer cells 
boron concentrations that are higher than that achieved with the current 
benchmark material (BPA). The same investigations indicated that owing to 
the extend of H-bonding interactions these compounds are more stable than 
their tertiary amine structure would suggest.     
 
Carbohydrates 
Boronated glyco-conjugate derivatives, such as glycosides, have 
attracted significant interest as potential vehicles for the delivery of boron,91 
since their precursor glyco-conjugates are important in several biological 
processes that include cell growth, intercellular communication and 
intracellular recognition processes.92,93 Glycoproteins-based targeting is 
guided by carbohydrate receptor-specific sites at the cell surface and by the 
expression of lectins at tumour cells.94 Boronated glyco-conjugate formation is 
normally facilitated by glycosidic bonds between the carborane unit and the 
carbohydrate moiety.95 To impart water solubility to such conjugates,91 the 
hydrophilic-lipophilic balance of the molecule may be adjusted by elongating 
the hydroxyl group-decorated carbohydrate moiety. An alternative approach to 
the synthesis of carboranyl carbohydrates involves the in situ formation of the 
boron cage. By means of this methodology, Tietze et al.96 prepared a series of 
carboranyl glycosides which have shown promise in tests involving melanoma 
cell lines (B-16) and rat glioma cells (C6), but in vivo tests demonstrated that 
the concentration of these compounds in blood was maintained at levels that 
are unacceptably high for meaningful use in therapy. 
Since this class of compounds has been studied widely and because 
glucose uptake and glycolytic metabolism are amplified in most tumors, this 
class of compounds merits further investigations. 
 
Nucleic bases 
The observation that boronated nucleosides are retained in tumour 
cells due to their amenability to 5’-monophosphorylation by thymidine kinase 1 
and deoxycytidine kinase has provided the driving force for the synthesis of 
boronated nucleic acids for BNCT applications.97,98 Lesnikowski et al.99 have 
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argued that the performance requirements that inform the molecular design of 
such molecular structures are the high tagging efficiency of 10B to tumour 
cells, the improved lipophilicity of the compound as compared with the 
precursor nucleoside, and the efficacy of intracellular uptake.  To this end, the 
same workers99 suggested the addition of a linker between the carboranyl 
moiety and the 5-position of the uracil group and also proposed that 
nucleotides are used in conjunction with oligomers, as this compilation imparts 
resistance to enzymatic digestion, increases lipophilicity and promotes the 
formation of a stable duplex molecule within the oligonucleotide chain.99  
Since negatively charged cluster have been shown to adversely 
influence the ability of nucleosides to cross biological barriers, closo-
carboranes have received more attention than nido-carboranes.100 Two main 
approaches have been adopted in molecular design: the first links the 
carborane to the ribose portion of the nucleoside, and the second attaches it 
to the base portion. Because of the lack of selective uptake presented by 
these compounds, and because of the narrow window of substrate 
modifications that the enzymes involved in DNA synthesis are able to accept, 
there are only a few examples of nucleosides bearing a carborane at the 
ribose site. Nucleosides bearing a substituent at the 5-position (e.g. 5-iodo or 
5-bromo-2´deoxyuridine) are very good substrates for enzymes involved in 
DNA synthesis, and are able to replace thymidine during this process.101 
Schinazi et al.102 and Yamamoto et al.103 respectively synthesised compounds 
14 and 22 (Figure 4) and evaluated them in vitro and in vivo. Compounds 22 
effected increased survival in mice, while studies involving enzymes 
suggested that the cellular uptake of 22 may be mediated by a nucleoside 
base transporter.  
 
Figure 4.  
 
Towards the improvement of the targeting specificity of boron 
compounds,104 the use of boron-rich carboranyl pyrazole-pyrimidines is 
reported through tests involving human cell lines to afford improved in vitro 
binding affinity. 
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Carborane-decorated pyrimidine rings are known to combine high 
boron content with good hydrolytic stability. In parallel, quinazolines, which 
may be regarded as hydrophobic analogues of pyrimidines, are known to 
display high affinity for the nucleic acids present in tumour cells.105 Zhou et 
al.106 have shown that hydrolytic stability is influenced by the number of 
hydroxyl-boryl groups in the molecular structure and that the biochemical 
properties of such compounds are highly sensitive to the presence of bulky 
aromatic groups. On the basis of this work it has been proposed that the 
carborane cage may be preferentially linked to the quinazoline group via a 
thioester linker.107 
The involvement of nucleic bases in cell processes and their 
associated ease of uptake by means of dedicated transport systems render 
these materials candidate carriers of boron for BNCT. However, since 
enzymes involved in the synthesis of DNA operate within the strict confines of 
substrate recognition, considerable research effort must be directed towards 
the establishment of the rules of molecular design.  
 
Triazine derivatives    
Several studies have utilised the synthetic versatility of the nucleophilic 1,3,5-
triazine ring for the preparation of BNCT agents. Ortho-carboranylthiolate-
substituted 1,3,5-triazines have been synthesised by the research group led 
by Lee,108 who through the introduction of a further molecular moiety effected 
improved biological activity through the bestowment of increased aqueous 
solubility to the structure. Preliminary in vitro studies indicated that many of 
these triazines effect the highly efficient accumulation of boron to B–16 
melanoma cells but are excessively cytotoxic.   
 
Porphyrins and phthalocyanines 
Dependent upon molecular structure, porphyrins have been shown to 
accumulate into the cytoplasm or at subcellular organelles (mitochondria, 
lysosomes, the Golgi apparatus, the endoplasmic reticulum or, in some cases, 
the nucleus).109 This property, coupled with low dark toxicity and amenability 
to activation by red light, renders porphyrins useful photosensitizers for 
applications in photodynamic therapy (PDT): upon exposure to red light they 
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produce singlet oxygen,110 triggering mechanisms of cell death by necrosis 
and/or apoptosis.111 Studies by Dass et al.112 and also by Keefe et al.113 have 
shown that porphyrins are taken up preferentially by tumours where they 
become accumulated and persist for prolonged periods of time. 
The use of porphyrins in BNCT, first proposed by Dougherty,114 led to 
investigations of means for the attachment of porphyrins to boron cages such 
that targeting specificity may be achieved.115 One such strategy exploits 
variations in the expression of High- and Low-Density Lipoprotein 
(respectively, HDL and LDL). To assess in vivo transport, Polo et al.116 
attached hematoporphyrins to both HDL and LDL. Further studies provided 
evidence for the LDL receptor-mediated uptake of benzoporphyrin derivatives, 
but also suggested that the associated acetylation of LDL prevents cellular 
accumulation.117 Towards the design of a molecular structure that anchors 
readily to biological substrates and is capable of inducing damage to DNA and 
RNA, Eason et al.118 considered the derivatives of an amphiphilic closo-
carboranyl-porphyrin functionalised at opposite ends of the with a quaternary 
ammonium functionality and a negatively charged phosphonate water 
solubilizing group. 
The synthesis of boronated porphyrins may be achieved by either 
condensing boronated aldehydic compounds with pyrrole, or by attaching 
boron moieties to the porphyrinic rings. The former approach has been used, 
by Haushalter et al.119 for the first synthesis of a carboranyl-containing 
porphyrin, while the latter method is sufficiently versatile to be used with many 
functional groups, including esters, amides or double bonds. Carborane 
moieties may be easily transformed into their corresponding nido-form, 
conferring increased solubility in aqueous media to the resulting boronated 
porphyrin. Efforts towards the synthesis of boronated porphyrins have been 
reviewed by Pietrangeli et al.120 Although many boronated porphyrins have 
been prepared to date, only a few have reached the clinic, primarily because 
of the need for a better understanding of their mechanism of tissue-selectivity, 
retention and biochemical action.109 Tested in rats bearing C6 cerebral 
gliomas, the tetrakis-carborane-carboxylate ester of 2,4-bis-(α,β-
dihydroxyethyl) deuterioporphyrin IX (BOPP, compound 23, Figure 5) at 48 
hours after administration (100 mg/kg of body weight) exhibited tumour/normal 
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brain ratios of 400:1 and tumour/blood ratios of 11:1.121 Infusion of BOPP in 
the RG2 rat glioma model at 12 mg/kg of body weight, showed a lower, but 
still favourable, tumour/normal brain ratio of 13:1 and a tumour/blood ratio of 
6:1.122 Munday et al.123 identified functional mitochondria as the major in vivo 
cellular target of BOPP after uptake and photo activation. These results 
however could not be replicated in a Phase I clinical trial: BOPP could not 
deliver to the tumour a therapeutic amount of boron in patients suffering from 
GBM, while its toxicity limited considerably the dose that could be 
administered. 
 
Figure 5.  
 
Encouraging results have been obtained with porphyrins carrying two 
carborane cages per molecule, such as the carboranyl protoporphyrin IX 
derivative (PP-IX, compound 24, Figure 5), which at high doses gave 
tumour:normal brain ratios of 6:1 and tumour:blood ratios of 10:1.124 
Since porphyrins are amenable to complex formation with certain 
metals (Ni, Cu, Mn), their biodistribution may be readily evaluated through the 
use of radioactive chelate congeners. Representative examples of this class 
of compounds are the metal tetraphenylcarboranyl porphyrins (MTCP) (Figure 
5) synthesised by Miura et al.;125 nickel tetraphenylcarboranyl porphyrins 
(NiTCP) (compound 25), tetraphenylhydrocarboranyl porphyrin (NiTCPH) 
(compound 26), and copper tetraphenylcarboranyl porphyrin (CuTCP) 
(compound 28) are associated with favourable tumour/normal brain and 
tumour/blood concentration ratios. Notably, NiTCPH (compound 26) has been 
shown to deliver 100 μg of 10B/g of tumour tissue, and to achieve 
tumour/normal brain concentration ratios of 50:1 and tumour/blood 
concentration ratios >500:1. 
Vicente et al.126 studied a 36 boron atom water-soluble meso-
substituted porphyrin (H2TCP), which at 100 µM showed no significant 
cytotoxic effect against murine melanotic melanoma cells in the dark but upon 
irradiation with red light caused cell mortality at the 20 µM level.   
Owing to their structural analogy with porphyrins, some 
phthalocyanines have been investigated as potential boron carriers,127 as is 
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exemplified by the boronated metal-phthalocyanine 73 prepared by Kahl et 
al.128 (Figure 5). 
 
Delocalized lipophilic cations  
Several Delocalized Lipophilic Cations (DLC) are known to accumulate 
selectively in tumour cells.129 These include the mitochondrial dye rhodamine 
123, tri-phenyl-methyl-phosphonium (TPMP) iodide, and 
tetraphenylphosphonium (TTP) chloride. The DLC structure interacts 
selectively with tumour cells as a consequence of the ~60 mV difference 
between the mitochondrial transmembrane potential of healthy and cancer 
cells.131 The resonance-stabilized positive charge of DLCs combined with their 
inherent lipophilicity, effect a significant decrease in the cost associated with 
the free energy change that accompanies the diffusion of DLCs through cell 
membranes, and lead to a >100 fold accumulation of DLCs in the 
mitochondrial matrix of tumour cells, in addition to the high difference (>5 fold) 
in the cytoplasmic and extracellular concentrations.38 Consequently, DLCs are 
considered to be promising carrier moieties for mitochondria-selective, target-
specific boronated anticancer agents. The plasma membrane potential 
(typically 30-60 mV, negative inside) also drives the accumulation of cations 
into the cells where they are then further accumulated into mitochondria, with 
90-95 % of intracellular cations being localized in mitochondria.132 
Adams et al.133 have synthesised a carboranyl derivative of 
dequalinium that exhibits in vitro tumour uptake and toxicology that are similar 
to those characterising its non-boronated analogue. In vitro, DEQ-B was seen 
to be taken up and retained in KB, F98 and C6 tumour cell lines, but not in the 
normal epithelial cell line CV1. At low concentrations, DEQ-B was shown to be 
less toxic in the normal cell line. The uptake, retention and toxicity of DEQ-B 
were found to be comparable with those of other non-boronated DLCs, such 
as dequalinium chloride, rhodamine 123 and tetraphenylphosphonium 
chloride.133  
The synthesis and preliminary in vitro evaluation have been reported134 
of 4-ortho- and 4-meta-carboranyl-N-(9-(diethylamino)-5H-
benzo[a]phenoxazin-5-ylidene) butanamide (30 and 31) and of the salts 
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dequalinium bis-nido-carborane (32), rhodamine-123-nido-carborane (33) and 
tetraphenyl phosphonium nido-carborane (34); Figure 6.  
 
Figure 6.  
 
These compounds were tested in vitro against human prostate 
epithelial carcinoma (PC3) and normal (PNT2) cell lines, and the amount of 
10B taken up by cells was evaluated by inductively coupled plasma-mass 
spectrometry (ICP-MS). Accumulation ratios (PC3/PNT2) were found to be 3.1 
for compound 30, 2.2 for compound 31, 4.2 for compound 32, 3.0 for 
compound 33, and 3.1 for compound 34.134 All tested compounds facilitated 
the tumour-cell accumulation of therapeutically relevant concentrations of 10B. 
Consistent with the expected increase in the membrane potential in the 
mitochondria of carcinoma cells, in all cases the percentage of 10B taken up 
by PC3 cells was somewhat higher than the corresponding uptake by PNT2 
cells.134 Compounds (Figure 6) that do not present a covalent link between the 
DLC and the boron moiety have afforded therapeutical amounts of boron 
intercellularly, indicating that a covalent bond may not be necessary.135 It is 
possible that DLCs guide their boronated counter-ions to cancer cells. 
Alternatively, ionic boronated structure may have an inherent affinity for 
cancer cells. To further explore these findings, Tseligka et al.136 tested several 
DLC-functionalized carborane compounds in cultures of normal (MRC-5, 
Vero), cancer (U-87 MG, HSC-3) and primary glioblastoma cancer stem cells 
(EGFRpos, EGFRneg). The pharmacological anticancer profile of these 
compounds revealed: a) significant in vitro selectivity, marked by a ~10× lower 
concentration needed to exert a cell growth-arrest effect on U-87 MG and 
HSC-3 than on MRC-5 and Vero; and, b) selective growth inhibition behaviour 
towards EGFRpos and EGFRneg cultures (>10× difference in potency) without 
the activation of apoptosis. Notably, and in marked contrast to cancer cells, 
normal cells are capable of recapitulating their full proliferation potential 
following exposure to DLC-carboranes. The pharmacological effects of DLC-
carboranes have been unveiled by the same study to be elicited at the 
molecular level through activation of the p53/p21 axis.136 
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Following in vivo studies that showed quick uptake, high selectivity (ca. 
10× higher than the currently used BNCT agents) and significant retention of 
triphenylmethylphosphonium iodide in canine brain tumor, the group of 
Rendina135 developed a series of water-soluble phosphonium salts containing 
carborane. The poor aqueous solubility of closo-carboranes led the group to 
investigate the deboronation and rearrangement of a closo-1,12-
dicarbadodecaborane to the zwitterionic nido-7,9-dicarbaundecaborane 
structure.137 The work built on that of Hawthorne138 who had demonstrated the 
improved water solubility of ionic carborane structures through investigations 
involving alkylphosphonium-closo-carborane salts. The promise of DLCs as 
an excellent means of imparting selectivity to boronated agents merits futher 
investigation, such that the relationships between chemical structure and 
biology activity are understood in sufficient detail to inform the optimisation 
strategies to molecular design.  
 
Existing drugs 
Several CNS depressants – including promazines, hydantoins and 
barbiturates – have been investigated as possible carriers of boron for BNCT. 
The interest in boronated promazines was first prompted by studies on the 
localization of chlorpromazine (CPZ) in melanoma-bearing rats.140 This 
compound exhibited selective accumulation in tumours (100 μg/g of tumour 
tissue, a tumour/normal tissue ratio >15) and a half-life of 10 days.140 In the 
1970s, Nakagawa et al.141 prepared a boronated CPZ analogue by attaching 
a nine boron atom cage to the nitrogen of the aliphatic chain; but probably 
because this nitrogen atom is involved in the substrate recognition for the 
compound’s intracellular transit, the results obtained were not very promising. 
Other boronated CPZ derivatives exhibited acceptable levels of toxicity but 
disappointing in vivo localization, which has been explained in terms of the 
accumulation of these chemicals into the liver.142 
Interest in the preparation of boronated barbiturates and hydantoins 
has been mainly fuelled by the observation that some of these compounds are 
able to enter the brain rapidly and achieve high tumour/normal brain 
concentration ratios. The first boronated barbiturates were synthesised in the 
1970s, but it was not until 1998 that Wyzlic et al.143 observed selective 
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accumulation following the preparation of a boronated barbiturate and 
hydantoin. However, little evidence was provided to indicate that these 
compounds possess characteristics that are prerequisite to candidate 
molecules for clinical evaluation. 
 
 
Organometallics 
Following the discovery of the antitumour activity of cisplatin (cis-
Cl2Pt(NH3)2), several metal-based compounds have been screened for their 
capability to target cancer cells. Bregadze et al.144 and Gielen et al.145 
synthesised compounds 35, 36 and 37 (Figure 7), which have been tested in 
vitro against several human tumour cell lines, including: Caucasian breast 
adenocarcinoma (MCF-7); colon carcinoma (WiDr); breast carcinoma (EVSA-
T); ovarian carcinoma (IGROV); melanoma (M19 MEL), and renal cancer 
(A498). The in vitro activities of 35 and 36 against MCF-7 were found to be 
comparable with the activity of doxorubicin, and the activity of 37 to be 
superior to that of cisplatin; the in vivo testing of 36 on rats bearing murine 
leukaemia (L1210) led to one mouse being cured. A systematic study of the 
influence of substituents R and R’, presented in Figure 7, found that the 
potency of agents is augmented if R = n-butyl.  
 
Figure 7.  
 
Tested against human cell lines in vitro, compounds 38, 39 and 40, which had 
been synthesised by Tiekink and Bregadze,146,147 displayed therapeutic 
activities that were deemed to be at least comparable with those of cisplatin, 
carboplatin or methotrexate. Notably, the most water-soluble compound of the 
series, triphenylstannate sodium salt 40, exhibits the highest cytotoxicity.  
In general, issues of low aqueous solubility and high cytotoxicity, even 
in the absence of neutron irradiation, have hindered the application of 
carborane-functionalized platinum (II) complexes in BNCT148149. 
In an effort to combine the potential advantages of the two main 
nuclides that are generally regarded as useful for applications in NCT, namely 
B and Gd, a complex (GdBLDL) which presents an o-carborane cage and an 
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MRI-probe moiety, Gd-DOTA monoamide, has been synthesised,150 but the 
therapeutic promise of the material has yet to be evaluated.  
 
 
 
Concluding remarks 
 
To fulfil its promise as the treatment of choice for brain cancers, BNCT 
requires 10B-rich drugs that can target selectively and accumulate 
preferentially in tumour cells. Although research efforts towards the design 
and synthesis of suitable candidates for BNCT have been considerable and 
span several decades, the multitude and complexity of the performance 
demands from such materials have acted co-operatively to impede progress. 
The advent of carborane chemistry has allowed the issue of achieving 
therapeutically useful concentrations of 10B in cancer tissue to be addressed 
and for methods to be developed towards the bestowment of target specificity. 
While both developments represent significant advances to BNCT chemistry, 
the issue of the efficient transport of the boronated active from the point of 
administration to the site of action, which is often complicated by biological 
barriers (the BBB being a case in point) represents a significant challenge that 
remains largely unaddressed.  
 
 
Figures captions 
 
Figure 1. BNCT steps: selective delivery of 10B-drugs to tumour cells is 
followed by irradiation with slow-moving neutrons (1n), leading to tissue repair.  
 
Figure 2. Structures of L-para-borophenylalanine BPA (1), L-phenylalanine 
(2), dimercaptooctachlorodecaborate 1,10-B10Cl8(SH)22- anion (3) and 
mercaptoundecahydrododecaborate (BSH) (B12H11SH)2- anion (4), ortho- (5), 
meta- (6) and para- (7) isomers of carboranes, and their interconversion. 
 
Figure 3. Structures of L-phenylalanine (2), L-o-carboranylalanine (CBA; 
compound 11), L-p-(o-carboran-1-yl)-phenylalanine (CBPA; compound 12), 
and L-O-(o-carboran-1-ylmethyl)-tyrosine (CBT; compound 13). 
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Figure 4. Nucleosides and deoxynucleosides bearing a carboranyl moiety in 
5-position. 
 
Figure 5. Structures of boronated porphyrins BOPP (compound 23) and PP-IX 
(compound 24); metal tetraphenylcarboranyl porphyrins NiTCP (compound 
25), NiTCPH (compound 26), NiNTCPH (compound 27) and CuTCP 
(compound 28); and carboranyl cobalt-phthalocyanine (compound 29). 
 
Figure 6. Structures of closo-carboranyl derivatives of Nile Blue (compounds 
30 and 31), and of the nido-carborane salts of dequalinium (compound 32), 
rhodamine-123 (compound 33) and tetraphenyl phosphonium (compound 34).  
 
Figure 7. Carboranyl-organotin compounds that show anti-tumour activity. 
 
 
Glossary 
Epithermal neutrons: A neutron having energy in the range immediately above 
the thermal range, roughly between 0.02 and 100 eV. 
Linear energy transfer: energy transfered to the material traversed per unit 
distance. 
Neutron capture cross section: describes the likelihood of interaction between 
an incident neutron and a target nucleus; measured in barns (b). 
Neutron fluence: measure of the intensity of neutron radiation as determined 
by the rate of flow of neutrons per area of tissue. 
Oxygen enhancement ratio: the ratio of radiation doses required to effect the 
same rate of cell death under oxic as under hypoxic conditions. 
Potentially lethal damage: DNA damage occurring due to irradiation. 
Relative biological effectiveness: the ratio of the doses required by two 
radiations to cause the same level of effect. 
Sublethal damage: sublethal damage is not lethal to cells, but can interact 
with similar damage from further radiation treatment to produce lethal 
damage. 
Thermal neutron: a neutron that is not bound within an atomic nucleus and 
that possesses an average kinetic energy of 0.025 electronvolts at room 
temperature. 
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